Oramed Pharmaceuticals Inc. (FRA:OJU1)
Germany
· Delayed Price · Currency is EUR 2.295
-0.045 (-1.92%)
At close: Dec 4, 2025
Oramed Pharmaceuticals Company Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.
Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Oramed Pharmaceuticals Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 4 |
| CEO | Nadav Kidron |
Contact Details
Address: 1185 Avenue of the Americas New York, Delaware 10036 United States | |
| Phone | 844 967 2633 |
| Website | oramed.com |
Stock Details
| Ticker Symbol | OJU1 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nadav Kidron | Chief Executive Officer |
| Avraham Gabay | Chief Financial Officer |
| Joshua Hexter | Chief Operating Officer |